Zimmer Biomet Inc.
ZBH | NYSE
$94.32
-$1.04 (-1.09%)
At close: Sep 21, 2026, 4:00 PM ET
$94.32
$0 (0.00%)
After-hours:
Sep 21, 2026, 4:08 PM ET
Company Profile
Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products. It operates through the following geographical segments: Americas, Europe Middle East and Africa, and Asia Pacific. The Americas segment consists of the U.S. and includes other North, Central and South American markets. The Europe Middle East and Africa segment includes France, Germany, Italy, Spain, and the United Kingdom. The Asia Pacific segment refers to the key markets such as Japan, China, Australia, New Zealand, Korea, Taiwan, India, Thailand, Singapore, Hong Kong, and Malaysia. The company was founded by Justin O. Zimmer in 1927 and is headquartered in Warsaw, IN.
Key Executives
| Name | Position |
|---|---|
| Ivan Tornos | President, Chief Executive Officer & Chairman of the Board |
| Angela Main | Senior Vice President, Global Chief Compliance Officer & Associate General Counsel of Asia Pacific |
| Chad F. Phipps | Senior VP, Chief Legal & Corporate Affairs Officer and Secretary |
| David DeMartino | Senior Vice President of Investor Relations |
| JehanZeb Noor | Senior VP, Chief Strategy, Business Development, Innovation & Transformation Officer |
| Jonathan Vigdorchik | Chief Science, Technology & Medical Affairs Officer |
| Kevin R. Thornal | Group President of Global Businesses & Americas |
| Paul A. Stellato | Interim CFO, VP, Controller & Chief Accounting Officer |
| Shaun Braun | Senior Vice President & Chief Information and Technology Officer |
| Wilfred van Zuilen | Group President of Europe, Middle East & Africa |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 13, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 12, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Aug 05, 2026 | 8-K | Current Report |
| Aug 05, 2026 | 4 | Filing |
| Aug 05, 2026 | 10-Q | Quarterly Report |
| Aug 05, 2026 | 8-K | Current Report |
| Aug 04, 2026 | 4 | Filing |
| Jul 23, 2026 | 3 | Filing |
| Jul 02, 2026 | 4 | Filing |
| Jul 02, 2026 | 4 | Filing |
Zimmer Biomet Inc.
| Country | United States |
| IPO Date | Jul 24, 2001 |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Employees | 17,000 |
| CEO | Ivan Tornos |
Contact Details
345 East Main Street Warsaw,
Indiana 46580 United States
Stock Details
| Ticker Symbol | ZBH |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001136869 |
| CUSIP Number | 98956P102 |
| ISIN Number | US98956P1021 |
| SIC Code | 3842 |
Recent News
- 4 days ago / zacks.comHere's Why Zimmer Biomet (ZBH) is a Strong Value Stock
- 13 days ago / gurufocus.comIs Zimmer Biomet Holdings Inc (ZBH) a Bargain After 3.9% Drop? GF Value Says Undervalued
- 14 days ago / prnewswire.comZimmer Biomet Announces Americas Leadership Promotions to Accelerate Commercial Transformation
- 18 days ago / zacks.comWhy Is Zimmer (ZBH) Up 1.8% Since Last Earnings Report?
- 21 days ago / seekingalpha.comZimmer Biomet - Showing Signs Of Life
- 22 days ago / zacks.comWhy Zimmer Biomet (ZBH) is a Top Value Stock for the Long-Term
- 25 days ago / prnewswire.comZimmer Biomet Announces Quarterly Dividend for Third Quarter of 2026
- 1 month ago / zacks.comIs Zimmer Biomet Stock Worth Retaining in Your Portfolio Now?
- 1 month ago / zacks.comHere's Why Zimmer Biomet (ZBH) is a Strong Momentum Stock
- 2 months ago / seekingalpha.comZimmer Biomet Holdings, Inc. (ZBH) Q2 2026 Earnings Call Transcript
Add to Watchlist
Select watchlists to add or remove ZBH